Clinical Trials Logo

Clinical Trial Summary

The main hypothesis is that the gait and postural deficits in the Caribbean form of PSP may be associated with a dysfunction of the cerebral cortex, as they result from sub-cortical involvement in classical forms. The investigators will characterize the gait and posture with a force platform to collect biomechanical gait parameters, coupled with the kinematic and electromyographic (EMG) study. Then the investigators realize a multimodal imaging study [structural magnetic resonance imaging (MRI) and diffusion tensor imaging (DTI)] that allow us to determine if a correlation can be found between the clinical characteristics of postural control and walking on one hand, and morphological changes and structural MRI changes in cortico-subcortical pathways on the other hand. The study of performance on neuropsychological tests, registration of ocular movements and the analysis of functional cortical activity will complete our multimodal approach. A better understanding of these disorders is expected to propose new drug treatment and rehabilitative strategies.


Clinical Trial Description

Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease (6/100 000 inhabitants) characterized by the association of Parkinson's syndrome, a paralysis of the verticality of the gaze and an alteration early balance and walking with the onset of falls during the first year of evolution of the disease. From a neuropathological point of view, it is characterized by a tauopathy with neurodegeneration within the basal ganglia, cerebellum, and midbrain (which includes the mesencephalic locomotor region-MLR).

In the Caribs this pathology is abnormally frequent (incidence over 3 times higher than expected), and represents 1/3 of the total Parkinsonian syndromes. In these patients, cortical pathology predominates leading to different cognitive deficit relative to patients with the classical form of PSP. Conversely, in PSP patients, imaging data suggest a preferential midbrain-thalamocortical pathway dysfunction. Pathophysiological mechanisms causing gait disturbances and postural control presented by these patients remains however not fully elucidated . In patients with Caribbean PSP, of which the clinical features are specific, gait disorders and falls appear later in the course of the disease (2.5 years on average) suggesting perhaps a different physiopathological mechanism. Consequently weak knowledge of the mechanisms involved, none specific treatment is currently available and the taking in therapeutic charge of these disorders rests essentially on a re-educative approach that remains poorly codified.

In this study, gait and balance disorders will be recorded using a force platform, coupled with kinematic study and EMG in patients with classical form of PSP and Caribbean one, and in controls. The functional and anatomy of brain will be examined using a multimodal brain imaging approach (with DTI. Performance in neuropsychological tests and oculomotor movements will also be measured. A comparative and correlation analyses will be performed to assess the link between gait, balance, oculomotor and cognitive performances and brain anatomy, and the differences between subjects groups. Caribbean PSP patients are recruited from Neurology and Physical Medicine and Rehabilitation of University Hospital of Pointe-à-Pitre and Fort de France, Classical PSP patients are be recruited from the Centre d'Investigation Clinique (CIC) of the Pitié-Salpêtrière hospital, and healthy volunteers from both centers. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04096651
Study type Interventional
Source Centre Hospitalier Universitaire de Pointe-a-Pitre
Contact
Status Completed
Phase N/A
Start date September 28, 2015
Completion date July 12, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT02194816 - Modifiable Variables in Parkinsonism (MVP)
Completed NCT00703677 - A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration Phase 1/Phase 2
Completed NCT00382824 - Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP) N/A
Completed NCT04184063 - Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) Phase 2
Recruiting NCT04706234 - Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies
Recruiting NCT04472130 - Neurodegenerative Diseases Registry
Recruiting NCT04139551 - Oxford Study of Quantification in Parkinsonism
Completed NCT02734485 - Deep TMS for the Treatment of Patients With Parkinson's Disease and Progressive Supranuclear Palsy N/A
Completed NCT01110720 - Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy Phase 2/Phase 3
Completed NCT01174771 - Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration N/A
Completed NCT00465790 - Research of Biomarkers in Parkinson Disease Phase 0
Completed NCT02460094 - Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy Phase 1
Active, not recruiting NCT04993768 - A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) Phase 2
Recruiting NCT03225144 - Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Completed NCT03058965 - Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain Early Phase 1
Recruiting NCT02605785 - A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy N/A
Completed NCT01353183 - Analysis of the Enteric Nervous System Using Colonic Biopsies N/A
Completed NCT00385710 - Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine) Phase 2
Recruiting NCT05260151 - Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases
Active, not recruiting NCT04658199 - A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy Phase 1